Detalhe da pesquisa
1.
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
Diabetes Obes Metab
; 2024 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38679838
2.
Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1630-1634, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28417532
3.
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Diabetes Care
; 46(5): 1060-1067, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944059
4.
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Diabetes Care
; 46(5): 1052-1059, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920867
5.
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
J Investig Med
; 66(3): 661-668, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29167192